Krishan Jethwa

#GI25 highlights #CommunityOnc:

1. #SCIENCE: Adv Eso SCC

2. #ESOPEC publication (Eso/GEJ/Ga)

3. Chemo in resectable Panc Ca

4. #StarterNET: GEP-NET

5. #CM8HW: dMMR/MSI-H mCRC

6. #BREAKWATER: BRAFV600E mCRC

7. ctDNA: #BESPOKE + SWOG80702

#OncSky #gism @ascocancer.bsky.social

1/8

25.01.2025 23:12 — 👍 11    🔁 2    💬 2    📌 0

🔥NRG GI-007🔥

LA-Esophagus Carcinoma
🔍 dCRT (50.4 Gy/28 fx carbo/taxol) + endoscopically injected oncolytic virus OBP-301

✅💯 cCR rate❗️
✅Comparatively favorable AE profile

👏🏽👏🏽 Brilliant work and looking forward to future study!!

#GI25 @ascocancer.bsky.social

25.01.2025 23:19 — 👍 1    🔁 0    💬 0    📌 0

🚨Pooled CAO/ARO/AIO-12 and OPRA Rectal trials🚨

Study suggests that selective WW compared with planned surgery offers:
✅ Comparable OS and DFS!!

🔥 Supports WW as a highly appropriate, and potentially preferable, option for patients with cCR after TNT‼️

#GI25 #CRC @ascocancer.bsky.social

25.01.2025 23:17 — 👍 2    🔁 1    💬 0    📌 0

@oncbrothers.bsky.social ‪
@ascocancer.bsky.social‬
@jrgralow.bsky.social
@mandyda.bsky.social
@heloisasoares.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social

25.01.2025 23:11 — 👍 0    🔁 0    💬 0    📌 0

🔥🔥🔥BREAKWATER🔥🔥🔥

BRAF V600E mut #CRC

SOC (FOLFOX) +/- encorafenib + cetuximab

EC + FOLFOX shows:

✅⬆️ORR
✅Strong suggestion of ⬆️OS

🚨EC + FOLFOX is a new SOC‼️

Pub available: idp.nature.com/authorize?re...

#GI25 @ascocancer.bsky.social

25.01.2025 23:11 — 👍 9    🔁 4    💬 1    📌 0

@oncbrothers.bsky.social ‪
@ascocancer.bsky.social‬
@jrgralow.bsky.social
@mandyda.bsky.social
@heloisasoares.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social

25.01.2025 23:08 — 👍 0    🔁 0    💬 0    📌 0

@oncbrothers.bsky.social ‪
@ascocancer.bsky.social‬
@jrgralow.bsky.social
@mandyda.bsky.social
@krishanjethwa.bsky.social
@heloisasoares.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social

25.01.2025 23:07 — 👍 0    🔁 0    💬 0    📌 0

🚨🚨CheckMate 8HW🚨🚨

🔥NEW SOC🔥

dMMR/MSI-H mCRC

Ph3 RCT 🔍 Nivo vs Ipi + Nivo

Ipi + Nivo offers:

✅⬆️ Early and sustained PFS
✅favorable safety profile

Pub available: www.thelancet.com/journals/lan...

#GI25 #crc @ascocancer.bsky.social

25.01.2025 23:06 — 👍 2    🔁 0    💬 1    📌 0

🚨SCIENCE Ph3 RCT🚨

🔥Check this one out!🔥
cT2-4N0-3, T1N2-3 Eso SCC

1️⃣neo Carbo + nab Paclitaxel + Sintilimab

2️⃣nCRT (41.4/23) w/ Carbo-taxol + Sintilimab

3️⃣nCRT

✅⬆️⬆️pCR CRT vs chemo (only 13% with chemo)
✅Sintilimab + CRT ⬆️ pCR (47%➡️60%) without added AEs

#GI25 @ascopost.bsky.social

23.01.2025 16:14 — 👍 4    🔁 0    💬 1    📌 0